Pulmonx Q4 revenue $13.7M (+39% YoY); FY2022 guidance $55M-$60M

Pulmonx Corp

2021-FY EPS reported -$1.35 revenue$48,416,000

Q4 2021 revenue $13.7M, up 39% YoY; FY2021 revenue $48.4M, up 48% YoY.
Gross margin improved to 74.8% in Q4 and 73.6% for FY2021, vs 72.0% and 64.8% a year ago.
Net loss Q4 $13.0M ($0.35/sh); FY net loss $48.7M ($1.35/sh).
FY2022 revenue guidance $55M-$60M; Q1 2022 guidance $9M-$10M, reflecting COVID impact.
U.S. treatment centers for Zephyr Valves expanded to 214, up 45% from start of 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.